Gallbladder and biliary diseases, including cholelithiasis and cholangitis, caused over 146,000 deaths globally in 2023, according to a recent report in The Lancet Gastroenterology & Hepatology. With more than 264 million people affected by these conditions, the burden of biliary pathology remains a significant public health challenge requiring urgent clinical attention.
Clinical Insights for Biliary and Gastrointestinal Health
- Gallbladder diseases, such as gallstones (cholelithiasis) and inflammation (cholecystitis), are reaching a global prevalence of over 264 million individuals.
- Low-dose amitriptyline is being evaluated as a targeted therapy for specific symptom profiles in patients suffering from irritable bowel syndrome (IBS).
- Rectal polyps require heightened clinical vigilance compared to colonic lesions due to a higher observed likelihood of invasive cancer and recurrence following endoscopic removal.
Global Mortality and Biliary Disease Prevalence
The latest data published in The Lancet Gastroenterology & Hepatology highlights a staggering global mortality rate of 146,000 deaths tied to gallbladder and biliary diseases. These conditions, which include the obstruction of bile ducts (cholangitis) and chronic inflammation, represent a major cause of morbidity. Global liver societies including the American Association for the Study of Liver Diseases (AASLD) issued consensus definitions for acute-on-chronic liver failure to better standardize how clinicians categorize and treat these high-risk patients. Hepatology introduced the group’s 78th president: Michael Ronan Lucey, MD, of the University of Wisconsin in Madison.
Amitriptyline and Large Rectal Polyp Management
Research published in Clinical Gastroenterology and Hepatology suggests that specific gastrointestinal and psychological symptom profiles may help identify which patients with irritable bowel syndrome (IBS) are likely to respond to low-dose amitriptyline. Meanwhile, a retrospective cohort study from Poland, appearing in Gut, found that patients undergoing endoscopic mucosal resections for large rectal polyps face a higher risk of recurrence and invasive malignancy than those with polyps located in the colon.
Disparities in Hepatitis C Treatment and Biologic Therapy
| Condition/Treatment | Clinical Finding | Source |
|---|---|---|
| Biliary Disease | 146,000 global deaths in 2023 | Lancet Gastroenterology & Hepatology |
| Rectal Polyps | Higher invasive cancer risk vs. colonic polyps | Gut |
| Hepatitis C | <25% of Medicaid patients treated in 6 months | HHS Office of Inspector General |
| Ulcerative Colitis | Ustekinumab efficacy vs. TNF inhibitors | Inflammatory Bowel Diseases |
References
- The Lancet Gastroenterology & Hepatology reported that over 264 million people globally had gallbladder and biliary diseases in 2023, contributing to more than 146,000 deaths.
